Human and Viral Interleukin-10 in Acute Epstein-Barr Virus-Induced Infectious Mononucleosis

Taga, Hiromi; Taga, Kazuyuki; Wang, Frederick; Chrétien, J; Tosato, Giovanna

doi:10.1093/infdis/171.5.1347

Cited by 45 publications

(31 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Reagents for vIL-10 ELISA were purchased from Pharmingen (San Diego, CA, USA). The ELISA was performed according to the manufacturer's general ELISA protocol which was also described elsewhere in detail [15]. In brief, 50 ml of rat anti-hIL-10/vIL-10 (clone JES3±9D7) was coated onto a Maxisorp Immunoplate (Nunc, Roskilde, Denmark) at a concentration of 1 mg/ml using 0.1 M Na 2 HPO 4 , pH 9.0 as binding buffer.…”

Section: Methodsmentioning

confidence: 99%

The Primary and Memory Immune Response to Epstein–Barr Virus Infection In Vitro is Characterized by a Divergent Production of IL‐1β/IL‐6 and IL‐10

et al. 2000

View full text Add to dashboard Cite

Jabs WJ, Wagner HJ, Schlenke P, Kirchner H. The Primary and Memory Immune Response to EPSTEIN± BARR Virus Infection In Vitro is Characterized by a Divergent Production of IL-1b/IL-6 and IL-10. Scand J Immunol 2000;52:304±308 Reactivation of latent Epstein±Barr virus (EBV) infection is considered to exert substantial immunomodulating activities. Little is known about EBV's modulating activities on cytokine production upon primary, in contrast to reactivated, infection. Therefore, we investigated the cytokine production of latently infected EBV-positive (EBV-pos) adults upon in vitro EBV stimulation compared to nonimmune age-matched EBVnegative (EBV-neg) donors. Production of interleukin (IL)-1b and IL-6 was strongly decreased in peripheral blood mononuclear cell (PBMC) cultures of EBV-pos adults; in contrast, IL-10 and IL-1 receptor antagonist exhibited signi®cantly higher levels. As expected, interferon (IFN)-g production was almost exclusively observed in EBV-pos donors; it was accompanied by a signi®cantly higher IL-12 synthesis. Experiments employing T cell-depleted PBMC showed similar cytokine levels between EBV-pos and EBV-neg individuals suggesting that reactivation of EBV-speci®c memory T cells was responsible for the divergent cytokine pro®les. Production of viral IL-10 was excluded as a reason for higher IL-10 levels in EBV-pos individuals. In conclusion, our results do not appear to relate to any primary immunological differences between EBV-neg and EBV-pos adults, but show that the EBV-speci®c memory response to latent EBV infection is characterized by some anti-in¯ammatory effects. This might be of relevance upon reactivation of latent EBV infection in vivo and provides further evidence that EBV infection acts in an immunomodulating fashion.

show abstract

Section: Methodsmentioning

confidence: 99%

The Primary and Memory Immune Response to Epstein–Barr Virus Infection In Vitro is Characterized by a Divergent Production of IL‐1β/IL‐6 and IL‐10

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Interestingly, the EBV late gene BCRF1 acts as an IL-10 homologue and shares 84% of its amino acid sequence with human IL-10 (135). During acute infectious mononucleosis, both viral and host forms of IL-10 are detected in sera (197). Host IL-10 is produced by monocytes and lymphocytes, functions to suppress T-cell proliferation and cytokine production, and can inhibit IFN-␥ production from T cells (137).…”

Section: Immune Response To Ebvmentioning

confidence: 99%

Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

2011

View full text Add to dashboard Cite

SUMMARY Epstein-Barr virus (EBV) is a gammaherpesvirus that infects a large fraction of the human population. Primary infection is often asymptomatic but results in lifelong infection, which is kept in check by the host immune system. In some cases, primary infection can result in infectious mononucleosis. Furthermore, when host-virus balance is not achieved, the virus can drive potentially lethal lymphoproliferation and lymphomagenesis. In this review, we describe the biology of EBV and the host immune response. We review the diagnosis of EBV infection and discuss the characteristics and pathogenesis of infectious mononucleosis. These topics are approached in the context of developing therapeutic and preventative strategies.

show abstract

“…Specifically, the Th2-type cytokines IL-4 and IL-10 sentation in the absence of costimulation and adhesion molecule expression (57,129,442). It may also induce an anerhave been implicated in the clonal deletion of alloreactive CD8 / T cells that mediate graft rejection; deletion of reac-gic state in CD4 / T cells (83), suppress production of the proinflammatory cytokine IL-2 by CD4 / T cells (81), inhibit tive cells was confirmed using a clonotypic antibody against the TCR expressed on the transgenic T cells used T-cell proliferation (407), and regulate expression of IFN-g and IL-4 by monocytes, dendritic cells, and Langerhans cells in the experiment (361).…”

Section: P26-8 / 9j0d$$ja01mentioning

confidence: 99%

Induction of Immunologic Tolerance for Transplantation

Rossini

Greiner

Mordes

1999

Physiological Reviews

121

View full text Add to dashboard Cite

Rossini, Aldo A., Dale L. Greiner, and John P. Mordes. Induction of Immunologic Tolerance for Transplantation. Physiol. Rev. 79: 99–141, 1999. — In the second half of the 20th century, the transplantation of replacement organs and tissues to cure disease has become a clinical reality. Success has been achieved as a direct result of progress in understanding the cellular and molecular biology of the immune system. This understanding has led to the development of immunosuppressive pharmaceuticals that are part of nearly every transplantation procedure. All such drugs are toxic to some degree, however, and their chronic use, mandatory in transplantation, predisposes the patient to the development of infection and cancer. In addition, many of them may have deleterious long-term effects on the function of grafts. New immunosuppressive agents are constantly under development, but organ transplantation remains a therapy that requires patients to choose between the risks of their primary illness and its treatment on the one hand, and the risks of life-long systemic immunosuppression on the other. Alternatives to immunosuppression include modulation of donor grafts to reduce immunogenicity, removal of passenger leukocytes, transplantation into immunologically privileged sites like the testis or thymus, encapsulation of tissue, and the induction of a state of immunologic tolerance. It is the last of these alternatives that has, perhaps, the most promise and most generic applicability as a future therapy. Recent reports documenting long-term graft survival in the absence of immunosuppression suggest that tolerance-based therapies may soon become a clinical reality. Of particular interest to our laboratory are transplantation strategies that focus on the induction of donor-specific T-cell unresponsiveness. The basic biology, protocols, experimental outcomes, and clinical implications of tolerance-based transplantation are the focus of this review.

show abstract

Human and Viral Interleukin-10 in Acute Epstein-Barr Virus-Induced Infectious Mononucleosis

Cited by 45 publications

References 12 publications

The Primary and Memory Immune Response to Epstein–Barr Virus Infection In Vitro is Characterized by a Divergent Production of IL‐1β/IL‐6 and IL‐10

The Primary and Memory Immune Response to Epstein–Barr Virus Infection In Vitro is Characterized by a Divergent Production of IL‐1β/IL‐6 and IL‐10

Progress and Problems in Understanding and Managing Primary Epstein-Barr Virus Infections

Induction of Immunologic Tolerance for Transplantation

Contact Info

Product

Resources

About